Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Francis

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Science (New York, N.Y.)|August 30, 2014
Is it time to destroy the smallpox virus?Isao Arita, Donald Francis
Transfusion|September 17, 2013
Closing the circle: a thirty-year retrospective on the AIDS/blood epidemicCorey Dubin, Donald Francis
Journal of Microbiological Methods|July 17, 2012
BAPJ69-4A: a yeast two-hybrid strain for both positive and negative genetic selectionHally Anne Shaffer, Michael Kenneth Rood, Badar Kashlan, et al.
Journal of the Medical Association of Thailand = Chotmaihet Thangphaet|January 10, 2008
Social harms in injecting drug users participating in the first phase III HIV vaccine trial in ThailandPunnee Pitisuttithum, Kachit Choopanya, Valai Bussaratid, et al.
Vaccine|November 17, 2011
HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/ERobert Paris, Sasitorn Bejrachandra, Prasert Thongcharoen, et al.
Plos Computational Biology|April 16, 2015
Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccineesIckwon Choi, Amy W Chung, Todd J Suscovich, et al.
The Lancet. Infectious Diseases|June 2, 2012
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144Merlin L Robb, Supachai Rerks-Ngarm, Sorachai Nitayaphan, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Science Translational Medicine|March 21, 2014
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccinesAmy W Chung, Musie Ghebremichael, Hannah Robinson, et al.
The Journal of Infectious Diseases|July 28, 2012
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm, Robert M Paris, Supamit Chunsutthiwat, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Science (New York, N.Y.)|August 30, 2014
Is it time to destroy the smallpox virus?Isao Arita, Donald Francis
Transfusion|September 17, 2013
Closing the circle: a thirty-year retrospective on the AIDS/blood epidemicCorey Dubin, Donald Francis
Journal of Microbiological Methods|July 17, 2012
BAPJ69-4A: a yeast two-hybrid strain for both positive and negative genetic selectionHally Anne Shaffer, Michael Kenneth Rood, Badar Kashlan, et al.
Journal of the Medical Association of Thailand = Chotmaihet Thangphaet|January 10, 2008
Social harms in injecting drug users participating in the first phase III HIV vaccine trial in ThailandPunnee Pitisuttithum, Kachit Choopanya, Valai Bussaratid, et al.
Vaccine|November 17, 2011
HLA class II restriction of HIV-1 clade-specific neutralizing antibody responses in ethnic Thai recipients of the RV144 prime-boost vaccine combination of ALVAC-HIV and AIDSVAX(®) B/ERobert Paris, Sasitorn Bejrachandra, Prasert Thongcharoen, et al.
Plos Computational Biology|April 16, 2015
Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccineesIckwon Choi, Amy W Chung, Todd J Suscovich, et al.
The Lancet. Infectious Diseases|June 2, 2012
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144Merlin L Robb, Supachai Rerks-Ngarm, Sorachai Nitayaphan, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Science Translational Medicine|March 21, 2014
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccinesAmy W Chung, Musie Ghebremichael, Hannah Robinson, et al.
The Journal of Infectious Diseases|July 28, 2012
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm, Robert M Paris, Supamit Chunsutthiwat, et al.
Pageof 2